Key Record Dates
| ClinicalTrials.gov Identifier: | NCT05232825 |
|---|---|
| Brief Title: | A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis (Ocarina II) |
| First Submitted : | January 27, 2022 |
| First Submitted that Met QC Criteria : | January 31, 2022 |
| First Posted : | February 10, 2022 |
| Last Update Submitted that Met QC Criteria : | January 13, 2023 |
| Last Update Posted : | January 17, 2023 |